Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation

MLA

Shanshan Huang, et al. “Combined Inhibition of MET and VEGF Enhances Therapeutic Efficacy of EGFR TKIs in EGFR-Mutant Non-Small Cell Lung Cancer with Concomitant Aberrant MET Activation.” Experimental Hematology & Oncology, vol. 13, no. 1, Oct. 2024, pp. 1–14. EBSCOhost, https://doi.org/10.1186/s40164-024-00565-9.

APA

Shanshan Huang, Yaling Long, Yuan Gao, Wanling Lin, Lei Wang, Jizong Jiang, Xun Yuan, Yuan Chen, Peng Zhang, & Qian Chu. (2024). Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation. Experimental Hematology & Oncology, 13(1), 1–14. https://doi.org/10.1186/s40164-024-00565-9

Chicago

Shanshan Huang, Yaling Long, Yuan Gao, Wanling Lin, Lei Wang, Jizong Jiang, Xun Yuan, Yuan Chen, Peng Zhang, and Qian Chu. 2024. “Combined Inhibition of MET and VEGF Enhances Therapeutic Efficacy of EGFR TKIs in EGFR-Mutant Non-Small Cell Lung Cancer with Concomitant Aberrant MET Activation.” Experimental Hematology & Oncology 13 (1): 1–14. doi:10.1186/s40164-024-00565-9.